Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective.

Slides:



Advertisements
Similar presentations
Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages
Advertisements

Risk of stroke and transient ischaemic attack after herpes zoster
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
R. Cavallo  Clinical Microbiology and Infection 
Evolution of the incidence of hepatitis B virus infection and immunization rates in a large French cohort born between 1960 and 1994  C. Ramière, L. Roche,
Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience  M.-C.
Core I97L mutation in conjunction with P79Q is associated with persistent low HBV DNA and HBs antigen clearance in patients with chronic hepatitis B 
Intrahepatic hepatitis B virus replication and liver histology in subjects with occult hepatitis B infection  D.K.-H. Wong, J. Fung, C.-K. Lee, W.-K.
I.J. Schalk  Clinical Microbiology and Infection 
Volume 147, Issue 1, Pages (July 2014)
Incidence and outcome of Staphylococcus aureus endocarditis—a 10-year single-centre northern European experience  H. Asgeirsson, A. Thalme, M. Kristjansson,
O.J. Dyar, G. Tebano, C. Pulcini  Clinical Microbiology and Infection 
Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis  T. Steinmetz, N.
Risk factors for cryptococcal infection among patients with rheumatoid arthritis receiving different immunosuppressive medications  T.-L. Liao, Y.-M.
Migrant health—a cause for concern?
T. Huwyler, L. Lenggenhager, M. Abbas, K. Ing Lorenzini, S. Hughes, B
C.-S. Lee, J.-H. Lee  Clinical Microbiology and Infection 
Emerging issues on hepatitis C virus infection after the introduction of the Directly Acting Antivirals  G. Ippolito  Clinical Microbiology and Infection 
J.-P. Van geertruyden  Clinical Microbiology and Infection 
Hepatitis B and C virus-related carcinogenesis
Virological tools to diagnose and monitor hepatitis C virus infection
Epstein–Barr virus (EBV) DNA in whole blood as a superior prognostic and monitoring factor than EBV-encoded small RNA in situ hybridization in diffuse.
Paradoxical immune reconstitution inflammatory syndrome associated with cryptococcal meningitis in China: a 5-year retrospective cohort study  S. Yan,
Treatment of complicated skin and skin structure infections in areas with low incidence of antibiotic resistance—a retrospective population based study.
Impact of inadequate initial antimicrobial therapy on mortality in patients with bacteraemic cholangitis: a retrospective cohort study  Y. Tagashira,
Multicentre surveillance of prevalence of the 23S rRNA A2058G and A2059G point mutations and molecular subtypes of Treponema pallidum in Taiwan, 2009–2013 
Hepatitis B virus basal core promoter/precore mutants and association with liver cirrhosis in children with chronic hepatitis B virus infection  Y.W.
Risk factors and outcome for colistin-resistant Acinetobacter nosocomialis bacteraemia in patients without previous colistin exposure  Y.-C. Wang, Y.-T.
Volume 68, Issue 3, Pages (March 2018)
Increased incidence of nitroimidazole-refractory giardiasis at the Hospital for Tropical Diseases, London: 2008–2013  L.E.B. Nabarro, R.A. Lever, M. Armstrong,
A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match–control study  M.-C. Tsai,
Volume 133, Issue 5, Pages (November 2007)
L. -W. Song, P. -G. Liu, C. -J. Liu, T. -Y. Zhang, X. -D. Cheng, H. -L
Vector control: a cornerstone in the malaria elimination campaign
Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non–severely ill patients 
Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis  J. Jung, M.Y. Kim, H.J. Lee, Y.S. Park, S.-O.
A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen- positive patients: a prospective cohort study in China  Y. Zhang,
Estimation of delay in detecting hepatitis C virus antibodies in pools compared to individual testing on seroconversion panels  B. Sarov, L. Novack, N.
Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice  J.E. Arends, P.A.M. Kracht, A.I.M. Hoepelman  Clinical.
Effects of gentamicin monotherapy for the initial treatment of community-onset complicated non-obstructive acute pyelonephritis due to Enterobacteriaceae.
L. Zhang, Q. Meng, S. Chen, M. Zhang, B. Chen, B. Wu, G. Yan, X
Serum hepatitis B core-related antigen is more accurate than hepatitis B surface antigen to identify inactive carriers, regardless of hepatitis B virus.
Metagenomics and probiotics
Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study  J.-Y. Feng, S.-F. Huang, W.-Y. Ting, Y.-C.
Hepatitis B and C virus-related carcinogenesis
Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected.
Sexually acquired Zika virus: a systematic review
Systematic review of antibiotic consumption in acute care hospitals
Treatment of hepatitis B in patients with chronic kidney disease
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up  N. Gianotti,
Accurate hepatitis C virus genotyping and selection of optimal therapy: lessons from a St Petersburg strain infection  E. Knops, E. Heger  Clinical Microbiology.
H. Leblebicioglu, C. Eroglu  Clinical Microbiology and Infection 
Gender differences in the outcome of community-acquired Staphylococcus aureus bacteraemia: a historical population-based cohort study  J. Smit, L.E. López-Cortés,
Increased intrahepatic quasispecies heterogeneity correlates with off-treatment sustained response to nucleos(t)ide analogues in e antigen-positive chronic.
Dynamics of hepatitis B virus quasispecies heterogeneity in association with nucleos(t)ide analogue treatment determined by MALDI-TOF MS  M. Rybicka,
Statin use and clinical outcomes among pneumonia patients
Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients  H.-Y. Pan, H.-Y. Pan,
Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis 
Z. Erjavec, H. Kluin-Nelemans, P.E. Verweij 
Virology: a scientific discipline facing new challenges
Modelling during an emergency: the 2009 H1N1 influenza pandemic
J.L. Balcázar  Clinical Microbiology and Infection 
Acquisition of second-line drug resistance and extensive drug resistance during recent transmission of Mycobacterium tuberculosis in rural China  Y. Hu,
J.A. Pérez-Molina, F. Fernández  Clinical Microbiology and Infection 
Impact of antibiotic restrictions: the patient's perspective
CMI readers' survey Clinical Microbiology and Infection
Rajko Saletinger, Mario Poljak, Franc Strle 
The future of diagnostic bacteriology
Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients  D. He, S. Guo, P. Zhu, S. Tao, M. Li,
Presentation transcript:

Comparison of the efficacy and safety of entecavir and tenofovir in nucleos(t)ide analogue-naive chronic hepatitis B patients with high viraemia: a retrospective cohort study  I.-T. Wu, T.-H. Hu, C.-H. Hung, S.-N. Lu, J.-H. Wang, C.-M. Lee, C.-H. Chen  Clinical Microbiology and Infection  Volume 23, Issue 7, Pages 464-469 (July 2017) DOI: 10.1016/j.cmi.2017.02.001 Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 1 Comparison of virological response between entecavir and tenofovir among hepatitis B e antigen (HBeAg) -positive (a) and HBeAg-negative (b) patients in propensity-score matching group. Clinical Microbiology and Infection 2017 23, 464-469DOI: (10.1016/j.cmi.2017.02.001) Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 2 Comparison of virological response between entecavir and tenofovir among all patients (a) and hepatitis B e antigen (HBeAg) -positive patients (b) with baseline hepatitis B virus DNA >8 log10 IU/mL. Clinical Microbiology and Infection 2017 23, 464-469DOI: (10.1016/j.cmi.2017.02.001) Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. 3 Comparison of hepatocellular carcinoma (HCC) between entecavir and tenofovir among all patients (a) and patients with cirrhosis (b). Clinical Microbiology and Infection 2017 23, 464-469DOI: (10.1016/j.cmi.2017.02.001) Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. S1.Comparison of hepatitis B e antigen (HBeAg) loss (a) and seroconversion (b) between entecavir and tenofovir among all HBeAg-positive patients. Clinical Microbiology and Infection 2017 23, 464-469DOI: (10.1016/j.cmi.2017.02.001) Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Fig. S2.(a) Comparison of cumulative incidence of drug-related acute kidney injury (AKI) between entecavir and tenofovir. (b) Serial mean estimated glomerular filtration rate (eGFR) values during entecavir and tenofovir treatment. Clinical Microbiology and Infection 2017 23, 464-469DOI: (10.1016/j.cmi.2017.02.001) Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.